Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System
Key facts
- Who runs it
- Mitrassist Lifesciences Limited Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 5 people, planned
- Started
- 23 Mar 2026
- Expected to end
- 23 Oct 2028
- Type of study
- Interventional
- Treatments tested
- MitraFix® Transcatheter Mitral Valve System
- Record updated
- 30 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (29)Hide the full registry criteria
Who can take part
- Moderate to severe or severe (≥3+) mitral regurgitation
- Age ≥ 18 years
- Patients at high risk for traditional open-heart surgery, defined as: STS mortality risk for mitral valve replacement ≥ 8%; OR presence of 2 or more frailty indices; OR presence of 2 or more major organ dysfunctions that cannot be improved post-operatively; OR other comorbidities or factors making them unsuitable for surgery
- Anatomically suitable for transcatheter MitraFix® system implantation via a transfemoral-transseptal approach as assessed by the investigator; the transfemoral-transseptal access route meets the requirements of the delivery system
- Able to understand the study purpose, voluntarily participate, sign the informed consent form, and willing to accept relevant examinations and clinical follow-ups
Who cannot take part
- Presence of previous implants in the mitral position (surgical bioprosthetic or mechanical valves, surgical annuloplasty rings, etc.)
- Concomitant tricuspid valve, aortic valve, or severe great vessel disease requiring surgical or interventional treatment
- Contraindications to anticoagulant/antiplatelet therapy that cannot be substituted or bridged
- Participation in another clinical study of an investigational device or drug within 3 months prior to screening that may interfere with this study
- Infective endocarditis or evidence of active infection
- Stroke or transient ischemic attack (TIA) within 90 days
- Severe untreated coronary artery disease or acute myocardial infarction within 90 days; or percutaneous coronary intervention (PCI)/coronary stent implantation within 90 days
- Severe pulmonary hypertension (resting PASP > 70 mmHg, assessed as irreversible)
- Severe allergy to iodine contrast media, nitinol, bovine-derived materials, or other device materials that remains intolerable despite premedication
- Any other conditions deemed unsuitable for enrollment by the investigator
- Left ventricular ejection fraction (LVEF) < 30%
- Chronic dialysis or expected need for long-term dialysis; or severe renal impairment (e.g., eGFR < 30 mL/min/1.73m²) unable to undergo perioperative dialysis
- Documented coagulopathy or severe hematological disorders (e.g., platelet count < 50×10\^9/L, active bleeding), or history of heparin-induced thrombocytopenia (HIT)
- Severe mitral stenosis
- Severe calcification of mitral leaflets and/or annulus; anatomical structures of the mitral valve apparatus (e.g., papillary muscles) unsuitable for device implantation
- High risk of left ventricular outflow tract obstruction (LVOTO) based on pre-operative CT/TEE planning (estimated neo-LVOT < 150 mm²), which cannot be avoided by procedural optimization
- Severe right ventricular dysfunction: Tricuspid Annular Plane Systolic Excursion (TAPSE) < 17 mm
- Extreme frailty preventing tolerance of the procedure, or in a state of shock requiring circulatory support
- Implantation of CRT, CRT-D, or implantable cardioverter-defibrillator (ICD) within 30 days
- Echocardiographic evidence of any intracardiac mass, or thrombus in the left ventricle or left atrium (including left atrial appendage)
- Contraindications to transesophageal echocardiography (TEE)
- Life expectancy < 12 months
- Pregnant or breastfeeding women
- Unsuitable for the transfemoral-transseptal approach (e.g., femoral vein diameter, calcification, tortuosity, or atrial septum/left atrial anatomy not meeting delivery system requirements)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mitral regurgitation
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery.
Read full original descriptionShow less
The main questions it aims to answer are:
Is the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life?
Participants will:
Receive the MitraFix valve through a small tube inserted into a vein in the leg.
Visit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.
The group in the trial
- MitraFix SystemTreatment being tested
Participants with moderate-to-severe or severe (≥3+) mitral regurgitation who are at high surgical risk will receive the MitraFix® Transcatheter Mitral Valve System.
Treatment: MitraFix® Transcatheter Mitral Valve System
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Clinical Study to Evaluate the Safety and Clinical Feasibility of the MitraFix® Transcatheter Mitral Valve System
- Criteria questions
- Built from NCT07501234, who can take part
- Record updated
- 30 March 2026